| Verified against primary record | |
| What a clinical outcome is | A measurable change in symptoms, overall health, ability to function, quality of life or survival[1] |
|---|---|
| The boundary it draws | A biomarker is not an assessment of how a patient feels, functions or survives[2] |
| Cross-border continuity data | None available at European Union level, as recorded in the Commission’s own evaluation[3] |
| Records read | Two definitional authorities, a Commission evaluation, two reviews, a registry standard and an information-request response, 9 October 2026 |
| Independently reported | |
| Quality of the evidence | Data on the outcomes of medical travel are insufficient and rarely generated using rigorous methods[4] |
| Bands apply only to the rows beneath them. No outcome figure for patients treated abroad is published here, because none was located. | |
Clinical outcomes in medical tourism are the single largest gap in the evidence on international medical travel. The concept is precisely defined in regulatory science, routinely measured inside national health systems, and almost entirely unmeasured for patients who cross a border to be treated.
What counts as an outcome
A clinical outcome is a measurable change in symptoms, overall health, ability to function, quality of life or survival that results from care given to patients, and one or more may serve as an endpoint in a clinical trial.[1] The instrument that captures it is a separate object: a clinical outcome assessment measures the change in a clinical outcome, and comes in four forms, reported by the patient, by a clinician, by an observer, or measured as a performance task.[1]
The boundary that makes the concept useful is stated most sharply in the harmonised terminology used by American regulators: a biomarker is not an assessment of how a patient feels, functions, or survives.[2] A blood result, a scan or a device reading is not an outcome. It is a measurement that may or may not predict one.
That distinction matters in this sector because what providers publish is usually neither. A photograph, a discharge summary, or a satisfaction score collected before the patient has flown home is not an outcome in this sense, and the three are treated in treatment success rates in medical tourism and patient satisfaction in medical tourism.
What the evidence base actually contains
Two independent assessments reach the same conclusion in their own words. A paper in the World Health Organization’s bulletin records that current data on the outcomes of medical travel are insufficient and rarely generated using rigorous methods, and that most of the available data on medical travel is of poor quality.[4] A programme of research commissioned in the United Kingdom records that there are no comprehensive data on inward and outward out-of-pocket and third party-funded flows, and states plainly of its own scope that the research did not set out to assess long-term clinical outcomes of medical tourists.[5]
At European level the position is recorded by the Commission’s own evaluation of the cross-border healthcare directive, which notes gaps and limitations in the data presented in the annual patient mobility reports and states that no quantitative data are available on the continuity of care between member states after cross-border treatment.[3] Continuity of care is the mechanism by which an outcome would be observed at all.
Why the data does not exist
The reason is not reluctance. It is that no field in the relevant records marks a patient as having been treated abroad, so the population cannot be assembled even in principle.
Two English hospital trusts have stated this in response to formal information requests. One recorded that its electronic records system does not record whether surgery took place overseas. The other stated simply that the trust does not hold the information requested.[6] These are administrative statements about data structure rather than findings about patients, and they are the clearest available evidence of why outcome research in this field cannot be done from routine records.
Device and implant registries show the same shape of limit. The national breast and cosmetic implant registry for the United Kingdom is specified to hold details of all breast implant procedures completed in England, Scotland and Northern Ireland, with all providers of breast implant surgery expected to participate.[7] That scope is territorial. The published standard says nothing about implants placed outside the United Kingdom, so the honest reading is that the question is unaddressed rather than that such implants are excluded. Either way, a device fitted abroad and revised at home enters the record, if at all, only at revision.
What would be needed
Three things, none of which currently exists together. A defined population, which requires a flag in a routine dataset marking treatment abroad. A validated instrument administered before and after treatment, which the national outcome programmes described in patient-reported outcome measures achieve for domestic patients and cannot reach for anyone treated overseas. And a follow-up period long enough for the result to declare itself, discussed in long-term outcomes of medical tourism.
Until those exist, statements about whether treatment abroad produces better or worse clinical results than treatment at home are not supported in either direction. The absence of evidence of harm is not evidence of safety, and the absence of evidence of benefit is not evidence of its lack.
See also
- Treatment success rates in medical tourism, why published rates are not comparable
- Complication rates in medical tourism, the surveillance windows that miss returning patients
- Long-term outcomes of medical tourism, follow-up horizons and what registries reach
- Patient-reported outcome measures, how outcomes are measured when they are measured
References
- National Center for Advancing Translational Sciences, National Institutes of Health. Clinical outcome, and Clinical outcome assessment. Registries and Data Standards glossary, undated. Verified against primary record: both glossary entries opened and read. Retrieved 9 October 2026.
- United States Food and Drug Administration and National Institutes of Health. BEST, Biomarkers, EndpointS and other Tools resource. June 2016. Verified against primary record: harmonised terminology resource opened and read. Retrieved 9 October 2026.
- Tetra Tech International Development, empirica and Asterisk Research and Analysis, for the European Commission Directorate-General for Health and Food Safety. Study supporting the evaluation of Directive 2011/24/EU, final report annexes. January 2022. Verified against primary record: Commission-published evaluation annexes opened and read. Retrieved 9 October 2026.
- Ruggeri K, Zalis L, Meurice CR, Hilton I, Ly TL, Zupan Z, Hinrichs S. Evidence on global medical travel. Bulletin of the World Health Organization, 2015;93:785-789. Independently reported: peer-reviewed paper in a World Health Organization journal. Retrieved 9 October 2026.
- Lunt N, Smith RD, Mannion R, Green ST, Exworthy M, Hanefeld J, Horsfall D, Machin L, King H. Implications for the NHS of inward and outward medical tourism. Health Services and Delivery Research, 2014;2(2), NIHR Journals Library. Independently reported: publicly commissioned peer-reviewed research. Retrieved 9 October 2026.
- Royal Devon University Healthcare NHS Foundation Trust, freedom of information response RDF3263-25, 2 April 2025, and Gloucestershire Health and Care NHS Foundation Trust, freedom of information response 412-2025, 8 April 2025. Verified against primary record: both published responses opened and read. Retrieved 9 October 2026.
- NHS England. Breast and Cosmetic Implant Registry. Information standard DAPB2132, effective 10 October 2016, page last updated 13 February 2026. Verified against primary record: published standard opened and read. Retrieved 9 October 2026.
Sourcing note: the definitional sources, the Commission evaluation annexes, the two reviews, the registry standard and the two information-request responses were opened and read on 9 October 2026. No clinical outcome figure for patients treated abroad is published in this entry, because none was located in any source consulted. The statement that no routine dataset flags treatment abroad rests on two named trusts’ own responses and on the territorial scope of the registry standard; it is reported as what those records say, not as proof that no such field exists anywhere.